T

    Talphera Inc. (TLPH)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $1.19
    -0.01 (-0.83%)

    Market Cap: $62.29M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    -13.44%
    Streak
    10 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.05 - $-0.05
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.07-40.0%
    60d ago$-0.07-40.0%
    30d ago$-0.07-40.0%
    7d ago$-0.07-40.0%
    Current$-0.05
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.01
    Range$-0.01 - $-0.01
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.01---
    Sep 26EST
    		-$-0.05---
    Jun 26
    		$-0.06$-0.07+14.29%Beat+40.0%
    Mar 26
    		$-0.05$-0.08+37.50%Beat+54.5%
    Dec 25
    		$-0.06$-0.07+20.00%Beat+14.3%
    Sep 25
    		$-0.11$-0.11+0.00%Beat+15.4%
    Jun 25
    		$-0.10$-0.11+9.09%Beat+33.3%
    Mar 25
    		$-0.11$-0.14+21.43%Beat+35.3%
    Dec 24
    		$-0.07N/A+56.25%Beat+72.0%
    Sep 24
    		$-0.13$-0.20+35.00%Beat-62.5%
    Jun 24
    		$-0.15$-0.20+25.00%Beat+63.4%
    Mar 24
    		$-0.17$-0.21+19.05%Beat+77.3%
    Dec 23
    		$-0.25$-0.20-25.00%Miss+75.0%
    Sep 23
    		$-0.08N/A+69.23%Beat+91.5%
    Jun 23
    		$-0.41$-0.53+22.64%Beat+64.3%
    Mar 23
    		$-0.75$-0.51-47.06%Miss+37.5%
    Dec 22
    		$-1.00$-0.10-900.00%Miss-1566.7%
    Sep 22
    		$-0.94$-1.20+21.67%Beat+32.9%
    Jun 22
    		$-1.15$-1.20+4.17%Beat+28.1%
    Mar 22
    		$-1.20$-1.20+0.00%Beat+25.0%
    Dec 21
    		$-0.06$-0.07+7.69%Beat+40.0%
    Sep 21
    		$-1.40$-1.40+0.00%Beat+30.0%
    Jun 21
    		$-1.60$-1.60+0.00%Beat+0.0%
    Mar 21
    		$-1.60$-1.70+5.88%Beat-700.0%
    Dec 20
    		$-0.10$-0.10+3.19%Beat+97.2%
    Sep 20
    		$-2.00$-1.80-11.11%Miss+37.5%
    Jun 20
    		$-1.60$-2.40+33.33%Beat+50.0%
    Mar 20
    		$-0.20$-0.17-17.65%Miss+94.1%
    Dec 19
    		$-3.60$-3.67+1.91%Beat-1900.0%
    Sep 19
    		$-3.20$-4.20+23.81%Beat+23.8%
    Jun 19
    		$-3.20$-4.52+29.20%Beat+20.0%
    Mar 19
    		$-3.40$-4.36+22.02%Beat+26.1%
    Dec 18
    		$-0.18$-0.20+10.00%Beat+10.0%
    Sep 18
    		$-4.20$-4.06-3.45%Miss+25.0%
    Jun 18
    		$-4.00$-3.80-5.26%Miss+31.0%
    Mar 18
    		$-4.60$-5.00+8.00%Beat+32.4%
    Dec 17
    		$-0.20$-0.20+0.00%Beat+4.8%
    Sep 17
    		$-5.60$-5.37-4.28%Miss-12.0%
    Jun 17
    		$-5.80$-5.64-2.84%Miss-
    Mar 17
    		$-6.80$-5.44-25.00%Miss-
    Dec 16
    		$-0.21$-0.24+12.50%Beat-
    Sep 16
    		$-5.00$-4.60-8.70%Miss-

    Key Metrics

    Valuation
    P/E Ratio-4.25EV/EBITDA0.11x
    Price/FCF-7.32xFCF Yield-13.65%
    Profitability
    Profit Margin0.00%Operating Margin-1000000.00%
    ROE-143.40%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio4.29xQuick Ratio4.29x
    Trading Statistics
    Beta0.70Avg Volume305.17K
    52-Week High$1.5752-Week Low$0.50

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.21
    SMA 20$1.28
    SMA 50$1.26
    SMA 200$1.03
    EMA 10$1.22
    EMA 20$1.25
    EMA 50$1.21
    EMA 200$1.02

    MACD

    Line: -0.02Signal: -0.01Hist: -0.01

    ADX

    ADX: 18.6+DI: 19.0-DI: 18.9

    Aroon & PSAR

    Aroon Up48.0
    Aroon Down52.0
    PSAR$1.42

    Bollinger Bands

    Upper Band$1.48
    Lower Band$1.08
    %B Position3167%(Upper)
    Band Width0.28

    RSI (14-Day)

    Neutral
    43.2

    Momentum Oscillators

    Stoch %K24.8
    Stoch %D29.6
    Williams %R-79.5
    ROC (10d)-0.8%
    Momentum-0.01
    CCI (20d)-66.7
    MFI (14d)21.1

    Volatility Measures

    ATR (14d)$0.07(6.1%)
    StdDev (20d)0.10
    Hist Vol63.6%(High)

    Volume Flow

    VWAP$1.19
    OBV125.5M
    AD Line-42.6M
    CMF (20d)-0.139

    Volume Metrics

    Avg Vol (20d)314.4K
    Vol Ratio0.1x(Low)
    VWMA (20d)$1.27

    Pivot Points

    R3$1.25
    R2$1.24
    R1$1.22
    Pivot Point$1.21
    S1$1.19
    S2$1.18
    S3$1.16

    Advanced Oscillators

    TSI-7.25
    Ultimate Osc43.2
    KST-54.16

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$1,000$0$27,000$6.68M$0$0$0$281,000$117,000
    Cost of Revenue$0$0N/A$0$0$0$1.32M$0$0$0$1.77M$0
    Gross Profit$0$0N/A$1,000$0$27,000$-1,323,000$0$0$0$281,000$117,000
    Operating Expenses$3.92M$3.95M$3.45M$3.42M$3.69M$2.94M$3.00M$3.75M$4.27M$4.24M$4.56M$3.43M
    R&D$1.69M$1.65M$1.56M$1.80M$1.50M$1.17M$1.32M$2.05M$1.91M$1.43M$1.77M$1.18M
    SG&A$2.23M$2.30M$1.89M$1.62M$2.19M$1.77M$1.67M$1.70M$2.36M$2.80M$2.79M$2.25M
    Operating Income$-3,924,000$-3,948,000$-3,453,000$-3,422,000$-3,693,000$-2,916,000$-2,996,000$-3,749,000$-4,270,000$-4,237,000$-4,283,000$-3,309,000
    Interest Income$172,000$169,000$203,000$81,000$83,000$69,000$103,000$155,000$201,000$220,000$171,000$187,000
    Interest Expense$388,000$0$319,000$1.01M$0$0$0$0$213,000$181,000$227,000$0
    Income Before Tax$-4,312,000$-2,556,000$-3,772,000$-4,436,000$-3,489,000$-2,666,000$-1,870,000$-3,353,000$-3,827,000$-3,954,000$-4,510,000$-1,416,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$2,000
    Net Income$-4,312,000$-2,556,000$-3,772,000$-4,436,000$-3,489,000$-2,593,000$-1,870,000$-3,353,000$-3,827,000$-3,954,000$-4,517,000$-1,357,000
    EBITDA$-4,637,000$-2,809,000$-4,100,000$-4,534,000$-3,572,000$-2,735,000$-1,973,000$-3,508,000$-3,864,000$-4,065,000$-4,690,000$-1,603,000
    EBIT$-4,484,000$-2,725,000$-3,975,000$-4,517,000$-3,572,000$-2,735,000$-1,973,000$-3,508,000$-3,815,000$-3,993,000$-4,681,000$-1,603,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TLPH

    News

    Conferencia de resultados del T2 de 2026 de Talphera (TLPH): la inscripción en NEPHRO CRRT alcanza el 75 %

    Talphera (TLPH) announced that enrollment in its NEPHRO CRRT study has reached 75%, with completion expected by late 2026 and a PMA application submission targeted for the first half of 2027. The company's cash balance was $17.1 million as of June 30, 2026, supplemented by an additional $16 million in conditional financing. Updated market research projects 200,000 CRRT procedures in the US by 2027, and the draft KDIGO 2026 guideline references nafamostat as a regional anticoagulant alternative.

    TradingKey•8/18/26•
    Bullish

    HC Wainwright Has Negative View of Talphera FY2029 Earnings

    HC Wainwright has lowered its FY2029 earnings per share estimate for Talphera (NASDAQ:TLPH) to $0.12 from $0.13, while reiterating a "Buy" rating and a $3.00 price target. The firm also projected FY2030 EPS at $0.32. Talphera's stock has a "Hold" consensus rating from analysts, with two Buy ratings, one Hold, and one Sell, and institutional investors own 37.67% of the company's shares.

    MarketBeat•8/14/26•
    Somewhat-Bearish

    Talphera (TLPH) Q2 2026 Earnings Call: NEPHRO CRRT Enrollment Reaches 75%

    Talphera announced that its NEPHRO CRRT study enrollment has reached 75%, with all clinical sites activated, keeping it on track for completion later in 2026. The company expects top-line data four to five weeks after enrollment finishes, aiming for a PMA submission in the first half of 2027. With $17.1 million in cash and conditional financing tranches totaling $16 million, Talphera anticipates funding operations through its projected 2027 approval.

    TradingKey•8/14/26•
    Bullish

    Q2 2026 Talphera Inc Earnings Call Transcript

    Talphera Inc. announced its Q2 2026 financial results, highlighting significant progress in its NEPHRO CRRT study with 75% enrollment completion. The company's Niyad (nafamostat) is gaining recognition as an acceptable regional anticoagulant in the 2026 KDIGO clinical practice guideline, expanding its market opportunity. Talphera has sufficient cash, including future financing tranches, to fund operations through a potential PMA approval in 2027, despite some inherent risks related to cash flow and the blinded study results.

    GuruFocus•8/13/26•
    Somewhat-Bullish

    H.C. Wainwright reiterates Talphera stock rating on trial progress

    H.C. Wainwright maintained a Buy rating and $3.00 price target for Talphera (NASDAQ:TLPH) after the company's Q2 2026 update, citing progress in its NEPHRO trial and reduced execution risk. Despite the stock's significant gains and positive trial updates, an InvestingPro analysis suggests it may be overvalued relative to its Fair Value. Talphera also recently reported Q2 earnings that matched Wall Street expectations.

    Investing.com•8/13/26•
    Neutral

    Frequently Asked Questions About TLPH

    Does TLPH pay dividends?
    Talphera Inc. (TLPH) does not currently pay a regular dividend.
    What is TLPH's market cap?
    Talphera Inc. (TLPH) has a market capitalization of $62.29M with a current stock price of $1.19.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In